NCT05498051 - Fluorescent Sentinel Lymph Node Identification in Colon Carcinoma Using Submucosal Bevacizumab-800CW. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 1, 2022

Primary Completion Date

February 1, 2023

Study Completion Date

June 1, 2023

Conditions

Colonic NeoplasmsSentinel Lymph NodeFluorescenceColorectal Neoplasms

Interventions

PROCEDURE

Sentinel lymph node identification

Therefore this prospective study aims to assess the safety and feasibility of lymph node identification using bevacizumab-800CW in patients with cT1-3N0-2 tumours, using peritumoral submucosal injections.

Trial Locations (1)

3813TZ

Meander Medisch Centrum, Amersfoort